| アブストラクト | INTRODUCTION/OBJECTIVE: To address the long-standing debate over the cardiovascular safety of Abacavir (ABC) in Human Immunodeficiency Virus (HIV) medicine, we directly compared two contemporary regimens sharing a dolutegravir (DTG)/lamivudine (3TC) backbone: DTG/ABC/3TC and DTG/3TC. We assessed whether the ABC-containing regimen was associated with disproportionate reporting signals for Major Adverse Cardiovascular Events (MACE). METHODS: We analyzed reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database covering 2020 Q1-2025 Q2, after consolidation by case identifier. Outcome-specific populations were created by excluding reports suggestive of pre-existing outcome-related conditions. Propensity score matching balanced measured covariates, and conditional logistic regression estimated Odds Ratios (ORs). RESULTS: For 3-point MACE, 1,642 matched pairs were analyzed. The ABC-containing regimen showed higher reporting odds (OR, 2.82; 95% confidence interval [CI], 1.62-4.91). Hypertension, dyslipidemia, and diabetes mellitus signals were also elevated. Age-only multiple imputation yielded a similar estimate; complete-case estimates were attenuated. CONCLUSIONS: These hypothesis-generating findings indicate cardiovascular and cardiometabolic reporting signals with the ABC-containing regimen; residual confounding and uncertain exposure-event timing preclude causal interpretation. |
|---|
| ジャーナル名 | Current HIV research |
|---|
| Pubmed追加日 | 2026/11/5 |
|---|
| 投稿者 | Hasebe, Shigeru; Tanaka, Masayuki; Iwane, Shiori; Tsuji, Toshikazu; Kushida, Hiroyuki; Kikuta, Maho |
|---|
| 組織名 | Department of Social Pharmacy, Faculty of Pharmaceutical Sciences, Setsunan;University, Osaka, Japan.;Laboratory of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Setsunan;Department of Pharmacy, National Hospital Organization Osaka Minami Medical;Center, Osaka, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42983939/ |
|---|
